VSELs therapy is a relatively new medical treatment that has shown great promise in the field of regenerative medicine. VSELs Therapy uses very small embryonic-like stem cells (VSELs), which are known to have an amazing healing capacity, as they can differentiate into various types of specialized cells. This makes them incredibly useful for regenerative treatments and has led to the development of VSELs therapy.
VSELs are found in the body in small amounts and can be harvested from blood or bone marrow. These cells can renew themselves and differentiate into different types of specialized cells, making them ideal for medical treatments. VSELs are small cells, corresponding in size to the cells in the inner cell mass of the blastocyst, and, depending on the measurement conditions (in suspension or after adhesion to slides), they measure5–7 μm in humans. Thus, they are slightly smaller than red blood cells and therefore require a special gating strategy during FACS sorting. Transmission electron microscopy analysis revealed that they have large nuclei containing euchromatin and a thin rim of cytoplasm enriched in spherical mitochondria, which are characteristic of early-development cells.
It has been proposed that VSELs originate from cells related to the germline, are deposited in developing organs during embryogenesis, and play a role as a backup population for monopotent tissue-committed stem cells. VSELs are quiescent but are activated during stress situations and mobilized into the circulation. The number of these cells decreases with age.6 Overall, the presence of these early-development cells in postnatal tissues challenges the accepted hierarchy within the adult stem cell compartment in bone marrow.
We propose that migratory primordial germ cells (PGCs), aside from their major role in establishing gametogenesis, may be a source of certain developmentally primitive stem cells (e.g., VSELs) that in bone marrow give rise to hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs) and are a source of mesenchymal stem cells (MSCs) and in other tissues a source of tissue-committed stem cells (TCSCs). Specification of VSELs into HSCs and EPCs may involve putative hemangioblast as an intermediate precursor cell. Dotted lines pathways still under investigation (adapted from reference).
VSELs express some embryonic stem cell markers, such as stage-specific antigen (SSEA), nuclear Oct-4A, Nanog, and Rex1. The true expression of these genes has been confirmed by the open structure of chromatin in their respective promoters, their association with histones promoting transcription, and by the sequencing of RT-PCR products. VSELs also express several markers characteristic of migrating PGCs, such as Stella and Fragilis. Our single-cell cDNA libraries revealed that the gene expression profile in murine BM-isolated VSELs, sorted as very small Sca-1+lin–CD45– cells, varies.10
VSELs residing in adult tissues are highly quiescent due to the erasure of regulatory sequences for certain paternally imprinted genes (e.g., at the Igf2–H19 locus) and thereby protected from insulin/insulin-like growth factor stimulation. They also express bivalent domains at genes encoding transcription factors in the homeobox family. Recent proteomic data have confirmed that genes involved in proliferation and cell signaling are expressed in VSELs at a low level and become upregulated during their expansion.
Evidence has accumulated that VSELs are at the top of the stem cell hierarchy in normal bone marrow, giving rise to HSCs, MSCs, and endothelial progenitor cells (EPCs). VSELs expand in vivo in response to stimulation by pituitary gonadotropins and gonadal sex hormones, which, from a developmental point of view, further links these cells to migrating PGCs.
VSELs therapy works by extracting blood from the patient. Within the plasma are dormant embryonic stem cells (VSELs), which are, for lack of a better word, “sleeping.” Once activated, the VSELs are introduced back into the body, where they can travel to sites of injury, inflammation, or disease and promote healing. These cells may also help restore the natural balance of stem cells in the body so that repair processes can occur more efficiently.
VSELs have also been shown to secrete molecules that help reduce inflammation and promote tissue regeneration. In addition to its therapeutic benefits, VSELs therapy also directly impacts the improvement of overall health and physical performance due to its ability to enhance cell renewal and regeneration.
MEDICLINK unique and patented VCELL® technique can activate "sleeping VSELs" and maximally expand in our lab. We are creating the most powerful clinical use regenerative medicines.
Reducing Biological Age: VSELs have the potential to reduce your current biological age by up to 3 years with a 2-hour treatment as measured by telomere length using a DNA methylation test. And treatment can be repeated every six months or so.
VSELs can differentiate into various types of cells, including muscle, bone, and cartilage cells. This can help repair and regenerate damaged tissues in the body.
VSELs Therapy has been shown to have potent anti-inflammatory effects. It can reduce the production of inflammatory cytokines and other markers of chronic inflammation, which can lead to a wide range of health problems.
VSELs Therapy can help stimulate the immune system, increasing the body’s ability to fight off infections and diseases.
VSELs Therapy can promote healing by increasing blood flow to damaged tissues, stimulating the growth of new cells, and reducing inflammation.
VSELs Therapy is a safe and effective treatment option for a wide range of health conditions. It is a minimally invasive procedure that has few side effects.
VSEL Therapy can be used to treat a variety of health conditions, including osteoarthritis, chronic pain, autoimmune disorders, and more.
VSELs therapy has been used to treat a variety of conditions and diseases, including.
general aging
athletic performance
old nagging injuries
inflammation
osteoarthritis
autoimmune conditions
heart disease
cancers
neurodegenerative diseases
soft tissue injury and damage
skin conditions
wounds
brain damage & degeneration
organ failure
strokes
spinal cord injuries
and more
MEDICLINK Regenerative Cellular Therapy Center has worked in regenerative medicines and stem cell clinical research for over 20 years, unique and patented VCELL® technique allow us to offer VSELs treatment consultation performed by experienced medical doctors and qualified healthcare professionals. Our treatments are tailored to your specific health condition and designed to help you get on the path to better health and well-being.
Contact us today to learn more about VCELL® therapy and how it can benefit you.
1.Ratajczak MZ, Ratajczak J, Kucia M. Very Small Embryonic-Like Stem Cells (VSELs). Circ Res. 2019 Jan 18;124(2):208-210. doi: 10.1161/CIRCRESAHA.118.314287. PMID: 30653438; PMCID: PMC6461217.
2.Bhartiya D, Jha N, Tripathi A, Tripathi A. Very small embryonic-like stem cells have the potential to win the three-front war on tissue damage, cancer, and aging. Front Cell Dev Biol. 2023 Jan 4;10:1061022. doi: 10.3389/fcell.2022.1061022. PMID: 36684436; PMCID: PMC9846763.
3.Bhartiya D, Shaikh A, Anand S, Patel H, Kapoor S, Sriraman K, Parte S, Unni S. Endogenous, very small embryonic-like stem cells: critical review, therapeutic potential and a look ahead. Hum Reprod Update. 2016 Dec;23(1):41-76. doi: 10.1093/humupd/dmw030. Epub 2016 Sep 10. PMID: 27614362.
4.Lahlil R, Scrofani M, Barbet R, Tancredi C, Aries A, Hénon P. VSELs Maintain their Pluripotency and Competence to Differentiate after Enhanced Ex Vivo Expansion. Stem Cell Rev Rep. 2018 Aug;14(4):510-524. doi: 10.1007/s12015-018-9821-1. PMID: 29736843; PMCID: PMC6013546.
5.Kassmer SH, Krause DS. Very small embryonic-like cells: biology and function of these potential endogenous pluripotent stem cells in adult tissues. Mol Reprod Dev. 2013 Aug;80(8):677-90. doi: 10.1002/mrd.22168. Epub 2013 Apr 4. PMID: 23440892; PMCID: PMC3740022.
6.Ratajczak MZ, Shin DM, Liu R, Mierzejewska K, Ratajczak J, Kucia M, Zuba-Surma EK. Very small embryonic/epiblast-like stem cells (VSELs) and their potential role in aging and organ rejuvenation--an update and comparison to other primitive small stem cells isolated from adult tissues. Aging (Albany NY). 2012 Apr;4(4):235-46. doi: 10.18632/aging.100449. PMID: 22498452; PMCID: PMC3371759.
7.Ratajczak MZ, Zuba-Surma EK, Shin DM, Ratajczak J, Kucia M. Very small embryonic-like (VSEL) stem cells in adult organs and their potential role in rejuvenation of tissues and longevity. Exp Gerontol. 2008 Nov;43(11):1009-17. doi: 10.1016/j.exger.2008.06.002. Epub 2008 Jun 14. PMID: 18601995; PMCID: PMC3174085.
8.Ratajczak MZ, Liu R, Ratajczak J, Kucia M, Shin DM. The role of pluripotent embryonic-like stem cells residing in adult tissues in regeneration and longevity. Differentiation. 2011 Mar;81(3):153-61. doi: 10.1016/j.diff.2011.01.006. Epub 2011 Feb 19. PMID: 21339038.
9.Ratajczak J, Zuba-Surma E, Paczkowska E, Kucia M, Nowacki P, Ratajczak MZ. Stem cells for neural regeneration--a potential application of very small embryonic-like stem cells. J Physiol Pharmacol. 2011 Feb;62(1):3-12. PMID: 21451204.
10.Ratajczak MZ, Liu R, Marlicz W, Blogowski W, Starzynska T, Wojakowski W, Zuba-Surma E. Identification of very small embryonic/epiblast-like stem cells (VSELs) circulating in peripheral blood during organ/tissue injuries. Methods Cell Biol. 2011;103:31-54. doi: 10.1016/B978-0-12-385493-3.00003-6. PMID: 21722799.
11.Shin DM, Liu R, Klich I, Wu W, Ratajczak J, Kucia M, Ratajczak MZ. Molecular signature of adult bone marrow-purified very small embryonic-like stem cells supports their developmental epiblast/germ line origin. Leukemia. 2010 Aug;24(8):1450-61. doi: 10.1038/leu.2010.121. Epub 2010 May 27. PMID: 20508611.